Cargando…

Perception of various stakeholders regarding clinical drug trial industry in India

CONTEXT: Though India has been thought to be an ideal destination for conduct of clinical drug trials, other smaller countries seem to be doing better. The pace of growth observed during 2005-2009 seems to be plateaued in 2010. AIMS: There is an urgent need for introspection and corrective actions....

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, Rakesh M., Pandia, Kirti, Goyal, Mahesh, Sharma, Meenakshi, Dolima, M. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications Pvt Ltd 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159214/
https://www.ncbi.nlm.nih.gov/pubmed/21897882
http://dx.doi.org/10.4103/2229-3485.83225
_version_ 1782210426066436096
author Parikh, Rakesh M.
Pandia, Kirti
Goyal, Mahesh
Sharma, Meenakshi
Dolima, M. S.
author_facet Parikh, Rakesh M.
Pandia, Kirti
Goyal, Mahesh
Sharma, Meenakshi
Dolima, M. S.
author_sort Parikh, Rakesh M.
collection PubMed
description CONTEXT: Though India has been thought to be an ideal destination for conduct of clinical drug trials, other smaller countries seem to be doing better. The pace of growth observed during 2005-2009 seems to be plateaued in 2010. AIMS: There is an urgent need for introspection and corrective actions. MATERIALS AND METHODS: An online survey was conducted among various stakeholders from clinical drug trial industry in India regarding their perception about clinical drug trial industry in India. Respondents were requested to rate training of investigator sites, industry, performance of regulatory, etc. RESULTS: Majority of respondent felt that the clinical drug trial industry in India is growing, though India is not utilizing its full potential. Lack of trained investigators and delay in regulatory approvals came out as biggest hurdles. CONCLUSIONS: Urgent steps need to be taken in terms of proper training of all stakeholders. Regulatory bodies ought to bring about some radical changes in the system so as to match the other competing nations.
format Online
Article
Text
id pubmed-3159214
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Medknow Publications Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-31592142011-09-06 Perception of various stakeholders regarding clinical drug trial industry in India Parikh, Rakesh M. Pandia, Kirti Goyal, Mahesh Sharma, Meenakshi Dolima, M. S. Perspect Clin Res Original Article CONTEXT: Though India has been thought to be an ideal destination for conduct of clinical drug trials, other smaller countries seem to be doing better. The pace of growth observed during 2005-2009 seems to be plateaued in 2010. AIMS: There is an urgent need for introspection and corrective actions. MATERIALS AND METHODS: An online survey was conducted among various stakeholders from clinical drug trial industry in India regarding their perception about clinical drug trial industry in India. Respondents were requested to rate training of investigator sites, industry, performance of regulatory, etc. RESULTS: Majority of respondent felt that the clinical drug trial industry in India is growing, though India is not utilizing its full potential. Lack of trained investigators and delay in regulatory approvals came out as biggest hurdles. CONCLUSIONS: Urgent steps need to be taken in terms of proper training of all stakeholders. Regulatory bodies ought to bring about some radical changes in the system so as to match the other competing nations. Medknow Publications Pvt Ltd 2011 /pmc/articles/PMC3159214/ /pubmed/21897882 http://dx.doi.org/10.4103/2229-3485.83225 Text en Copyright: © Perspectives in Clinical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Parikh, Rakesh M.
Pandia, Kirti
Goyal, Mahesh
Sharma, Meenakshi
Dolima, M. S.
Perception of various stakeholders regarding clinical drug trial industry in India
title Perception of various stakeholders regarding clinical drug trial industry in India
title_full Perception of various stakeholders regarding clinical drug trial industry in India
title_fullStr Perception of various stakeholders regarding clinical drug trial industry in India
title_full_unstemmed Perception of various stakeholders regarding clinical drug trial industry in India
title_short Perception of various stakeholders regarding clinical drug trial industry in India
title_sort perception of various stakeholders regarding clinical drug trial industry in india
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159214/
https://www.ncbi.nlm.nih.gov/pubmed/21897882
http://dx.doi.org/10.4103/2229-3485.83225
work_keys_str_mv AT parikhrakeshm perceptionofvariousstakeholdersregardingclinicaldrugtrialindustryinindia
AT pandiakirti perceptionofvariousstakeholdersregardingclinicaldrugtrialindustryinindia
AT goyalmahesh perceptionofvariousstakeholdersregardingclinicaldrugtrialindustryinindia
AT sharmameenakshi perceptionofvariousstakeholdersregardingclinicaldrugtrialindustryinindia
AT dolimams perceptionofvariousstakeholdersregardingclinicaldrugtrialindustryinindia